Clinical Trial News and Research

RSS

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.

22 Jul 2011

Michigan Cardiovascular Institute performs first Astron Pulsar stent procedure in the U.S.

BIOTRONIK announced today that the first endovascular procedure was completed in the BIOFLEX-I clinical trial—a trial set to evaluate the safety and performance of the Astron and Astron Pulsar self-expanding peripheral stents.

22 Jul 2011

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

UK regulators have approved Europe's first clinical trial of a monoclonal antibody produced from genetically modified plants. This landmark decision sets the stage for the testing, in humans, of an anti-HIV product made from genetically modified tobacco plants. It will open the door for trials of additional plant-derived medicines treating a range of diseases.

22 Jul 2011

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on July 22 the results of a randomized, Phase II clinical trial for the novel oral nucleoside antitumor agent TAS-102 under development by the company for metastatic colorectal cancer, at the 9th Annual Meeting of the Japanese Society of Medical Oncology held in Yokohama.

22 Jul 2011

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension.

22 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Quest receives U.S. patent allowance for cancer combination therapy

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease".

22 Jul 2011

Enrollment complete in Sapheon's clinical study of saphenous vein reflux disease treatment

Sapheon Inc. announced successful enrollment in a 30-patient, prospective, single-arm clinical study of the Sapheon Closure System — a single-use, minimally invasive approach to the treatment of saphenous vein reflux disease.

22 Jul 2011

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes its compound APC-100 was recently granted a patent in the United States.

22 Jul 2011

Neovasc to fund Tiara project with $4 million private placement

Neovasc Inc. today announced that it intends to complete a non-brokered private placement with accredited investors of up to four million equity units at the price of $1.00 per unit for aggregate gross proceeds of up to $4.0 million. The company expects that insiders will purchase approximately half of the units.

21 Jul 2011

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

BioSante Pharmaceuticals, Inc., today announced an exclusive worldwide license of its Melanoma Vaccine to The John P. Hussman Foundation, a charitable foundation that supports research to address life-threatening medical conditions and significant disabilities.

21 Jul 2011

Researchers discover novel combination of two mutations in a patient with ADHD

Often enough, in science as in life, unexpected knowledge has a personal impact. Researchers seeking rare gene variants in just a few individuals with attention-deficit hyperactivity disorder (ADHD) discovered that one patient had a novel combination of two mutations.

21 Jul 2011

Alexion second quarter net product sales of Soliris increase to $185.7 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris of $185.7 million in Q2, reflecting steady addition of new patients, compared to $125.8 million for the same period in 2010.

21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Pharmaceuticals can be produced by plants. Antibodies that have been produced in tobacco plants will now for the first time be tested in a clinical study.

21 Jul 2011

Portable robotic device, videogames can help patients to recover from stroke

Today 15 million persons throughout the world suffer from an ictus every year and 5 million are left with chronic disabilities. FIK designed a system for alleviating neuromuscular disability amongst these patients from their homes and by which these can be permanently supervised by the therapist who will be able to carry out a quantitative evaluation of the therapy. To this end, they have brought together new technologies and entertainment and a greater quality of rehabilitation.

20 Jul 2011

Three-drug regimen more effective for treating H. pylori infection

Helicobacter pylori, the bacterium known to cause peptic ulcers, is also the primary cause of gastric cancer, which is a leading cancer killer globally.

20 Jul 2011

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Some of the most aggressive forms of breast cancer are more vulnerable to chemotherapy when it is combined with a new class of anti-cancer agent, researchers from the Walter and Eliza Hall Institute have shown.

20 Jul 2011

Series of articles explore recent evidence-based vascular medicine

As the population ages and obesity and diabetes increase, more people suffer from noncardiac vascular diseases. In the July/August issue of Progress in Cardiovascular Diseases, published by Elsevier, a series of articles from recognized experts on key topics in vascular disease and endovascular medicine provide an insightful compendium of the evidence available to help improve the care of this complex patient population.

20 Jul 2011

EPA to expand Cooperative Research And Development Agreement with NanoLogix

NanoLogix, a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens.

19 Jul 2011

Clinical Trial News and Research

22nd Century receives FDA approval for X-22 IND to conduct Phase II-B smoking cessation trial

Michigan Cardiovascular Institute performs first Astron Pulsar stent procedure in the U.S.

UK regulators approve Europe's first clinical trial of plant-derived antibody for HIV

Taiho announces results of TAS-102 Phase II trial for metastatic colorectal cancer

Inotek completes two stages of INO-8875 Phase 2b trial against glaucoma

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

Quest receives U.S. patent allowance for cancer combination therapy

Enrollment complete in Sapheon's clinical study of saphenous vein reflux disease treatment

Adamis receives U.S. patent for APC-100 to treat prostate cancer

Neovasc to fund Tiara project with $4 million private placement

BioSante announces worldwide license of Melanoma Vaccine to Hussman Foundation

Researchers discover novel combination of two mutations in a patient with ADHD

Alexion second quarter net product sales of Soliris increase to $185.7 million

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Clinical study of anti-HIV antibody made from genetically modified tobacco plants

Portable robotic device, videogames can help patients to recover from stroke

Three-drug regimen more effective for treating H. pylori infection

Chemotherapy combined with anti-cancer agent shows promise for treatment of aggressive breast cancers

Series of articles explore recent evidence-based vascular medicine

EPA to expand Cooperative Research And Development Agreement with NanoLogix

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery